Novo’s oral semaglutide bests Lilly and Boehringer Ingelheim’s Jardiance in phase 3, but questions remain

2020-08-17T20:58:07+00:00Industry News|

Even as Novo Nordisk works to steal diabetes market share with its new GLP-1 drug Ozempic, it’s advancing an oral [...]